Two PAREXEL Executives Named to 2017 PharmaVOICE 100
August 01 2017 - 9:15AM
Business Wire
Chief Scientific Officer of PAREXEL and
Worldwide Head of The Medical Affairs Company recognized for
contributions to life sciences industry
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today announced that Sy
Pretorius, M.D., Senior Vice President and Chief Scientific
Officer, and Evan Demestihas, M.D., RPh, Vice President, Worldwide
Head of The Medical Affairs Company (TMAC), have been named to
PharmaVOICE magazine’s list of the 100 most inspiring people in the
life sciences industry. The honor, published in the July/August
2017 issue of PharmaVOICE, recognizes both leaders for their
valuable contributions to the industry and dedication to improving
patients’ lives, while also mentoring the next generation of
industry leaders.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170801005995/en/
Sy Pretorius, M.D., Senior Vice President
and Chief Scientific Officer (Photo: Business Wire)
Dr. Pretorius has been with PAREXEL for more than 20 years in
various international leadership roles. As Chief Scientific
Officer, he collaborates closely with biopharmaceutical and medical
device clients in designing and optimizing innovative drug / device
development strategies and plans. He also leads several PAREXEL
business units across three continents – including the Company’s
global Early Phase business, Global Medical Services, Quantitative
Clinical Development, as well as its Genomic Medicine unit.
Dr. Demestihas joined PAREXEL in February 2017, when the Company
acquired TMAC, a leading full-service Contract Medical Organization
(CMO). TMAC offers outsourced Medical Science Liaisons (MSLs),
Clinical Nurse Educators (CNEs) and other field medical teams in
addition to medical affairs consulting, medical information, and
direct placement services. A 30-year veteran of the pharmaceutical
industry, Dr. Demestihas has led TMAC from its founding in 2007. In
1997, Dr. Demestihas established the pharmaceutical industry’s
first CMO, Science Oriented Solutions (SOS), and led the company
for 10 years.
“We are proud that PharmaVOICE has recognized Dr. Sy Pretorius
and Dr. Evan Demestihas among this year’s 100 most inspiring people
in the life sciences industry. Their passion and dedication to drug
development is felt throughout PAREXEL and beyond,” said Josef von
Rickenbach, Chairman and CEO, PAREXEL. “Sy’s leadership in clinical
trial innovation has helped PAREXEL expand our capabilities and
service offerings to help our clients bring treatments to market
faster and more efficiently. Evan is a pioneer in the medical
affairs sector, who recognized a demand for medical affairs
solutions across the industry and created a successful breakthrough
business model. The leadership, innovation, and dedication that
both Sy and Evan bring to PAREXEL inspire our global workforce each
day.”
The annual PharmaVOICE 100 list honors a select group of leaders
in the life sciences who positively impact their colleagues, peers,
organizations, and the industry at large. These individuals are
passionate, forward-thinkers who actively work to address industry
challenges and trends. To read the 2017 PharmaVOICE profiles, visit
www.pharmavoice.com.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services company, providing a broad range of
expertise-based clinical research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology, and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the integrated
clinical development and regulatory information management process.
Headquartered near Boston, Massachusetts, PAREXEL has offices in 86
locations in 51 countries around the world, and had approximately
19,370 employees in the third quarter. For more information about
PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170801005995/en/
Media:Dana RobieTel.: +1 781-434-4772Email:
Dana.Robie@PAREXEL.comorJenny Radloff, PAN CommunicationsTel.: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1 781-434-4753Email: Ron.Aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2023 to Apr 2024